- Conditions
- Age-Related Macular Degeneration
- Interventions
- Fovista®, bevacizumab, ranibizumab, aflibercept
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 268
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Macular Edema
- Interventions
- Iluvien 0.19 MG Drug Implant, Aflibercept
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
- Procedure · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
- Conditions
- Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Interventions
- ziv-aflibercept, topotecan hydrochloride
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 257
- States / cities
- Anniston, Alabama • Mobile, Alabama • Tucson, Arizona + 174 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- GB-102, Aflibercept
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Prompt Laser, Prompt aflibercept, Deferred laser, Deferred aflibercept
- Procedure · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 100
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more
- Conditions
- Diabetic Macular Edema
- Interventions
- IVT Aflibercept, SC CLS-TA
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Mountain View, California • The Woodlands, Texas
- Conditions
- Vitreous Hemorrhage
- Interventions
- Intravitreal Aflibercept Injection, Standard Vitrectomy
- Drug · Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,775 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- VEGF Trap
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 204
- States / cities
- Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 148 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg, Aflibercept 2.0mg
- Drug
- Lead sponsor
- Arshad Khanani
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
- Interventions
- Aflibercept, foselutoclax
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more
- Conditions
- Brain Cancer, Gliomas
- Interventions
- [18F]FACBC PET and [18F]FLT PET imaging
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neovascular Age-related Macular Degeneration, nAMD
- Interventions
- ABP 938 8 mg, Aflibercept (US) 8 mg
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 55
- States / cities
- Fullerton, California • Long Beach, California • Modesto, California + 50 more
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Palmetto Retina Center, LLC
- Other
- Eligibility
- Not listed
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Augusta, Georgia • Lincoln, Nebraska • West Columbia, South Carolina + 3 more
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level, Aflibercept
- Drug
- Lead sponsor
- Oxurion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 18
- States / cities
- Huntington Beach, California • Pasadena, California • Sacramento, California + 15 more
- Conditions
- Recalcitrant Wet Age-related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Northern California Retina Vitreous Associates
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- Interventions
- EYE103, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 55
- States / cities
- Scottsdale, Arizona • Glendale, California • Modesto, California + 34 more
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- SOK583A1
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 5
- States / cities
- Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more
- Conditions
- Metastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Carcinoma, Non-small Cell Lung Cancer
- Interventions
- Aflibercept, Pemetrexed, Cisplatin
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Stanford, California + 11 more
- Conditions
- Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Biological
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more